[go: up one dir, main page]

AU2002220266A1 - Methods for the identification and the treatment of cardiovascular disease - Google Patents

Methods for the identification and the treatment of cardiovascular disease

Info

Publication number
AU2002220266A1
AU2002220266A1 AU2002220266A AU2026602A AU2002220266A1 AU 2002220266 A1 AU2002220266 A1 AU 2002220266A1 AU 2002220266 A AU2002220266 A AU 2002220266A AU 2026602 A AU2026602 A AU 2026602A AU 2002220266 A1 AU2002220266 A1 AU 2002220266A1
Authority
AU
Australia
Prior art keywords
identification
treatment
methods
cardiovascular disease
cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220266A
Inventor
Jeannette Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2002220266A1 publication Critical patent/AU2002220266A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002220266A 2000-11-09 2001-11-09 Methods for the identification and the treatment of cardiovascular disease Abandoned AU2002220266A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24818500P 2000-11-09 2000-11-09
US60/248,185 2000-11-09
US25741700P 2000-12-22 2000-12-22
US60/257,417 2000-12-22
PCT/US2001/047406 WO2002039122A2 (en) 2000-11-09 2001-11-09 Methods for the identification and the treatment of cardiovascular disease

Publications (1)

Publication Number Publication Date
AU2002220266A1 true AU2002220266A1 (en) 2002-05-21

Family

ID=26939172

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220266A Abandoned AU2002220266A1 (en) 2000-11-09 2001-11-09 Methods for the identification and the treatment of cardiovascular disease

Country Status (3)

Country Link
US (1) US20030166017A1 (en)
AU (1) AU2002220266A1 (en)
WO (1) WO2002039122A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194703A1 (en) * 2000-11-13 2003-10-16 Stacey Bolk Association of thrombospondin polymorphisms with vascular disease
JP2004121218A (en) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk Method for testing bronchial asthma or chronic obstructive pulmonary disease
US7655411B2 (en) * 2002-08-23 2010-02-02 W2 Holdings, Inc. Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
AU2012244071B2 (en) * 2003-10-09 2014-12-04 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
KR20080039878A (en) 2005-06-24 2008-05-07 카딜라 핼쓰캐어 리미티드 Trombospondin-1 Derived Peptides and Methods of Treatment
AU2007319576B2 (en) * 2006-10-06 2014-01-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
EP2192916A4 (en) * 2007-08-23 2012-04-04 Univ Leland Stanford Junior MODULATION OF SYNAPTOGENESIS
KR101040321B1 (en) 2007-11-21 2011-06-10 고려대학교 산학협력단 Biomarker for Diagnosing Cardiovascular Disease
KR101678703B1 (en) * 2008-10-29 2016-11-23 비쥐 메디신, 인코포레이티드 Galectin-3 immunoassay
MX2012002371A (en) * 2009-08-25 2012-06-08 Bg Medicine Inc Galectin-3 and cardiac resynchronization therapy.
CN107703109B (en) * 2016-08-08 2021-01-15 华东理工大学 Two-dimensional molybdenum sulfide polypeptide composite material and application thereof in targeting CD47 cancer marker
CN107653312B (en) * 2017-09-07 2021-10-15 中国医学科学院阜外医院 rs7901016 detection system related to blood lipid level and coronary heart disease and related applications
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
CN111007258A (en) * 2019-12-20 2020-04-14 首都儿科研究所附属儿童医院 Reagent for early diagnosis of Kawasaki disease and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256538A (en) * 1991-03-08 1993-10-26 Board Of Regents, The University Of Texas System Detection of early platelet activation and prediagnosis of thrombotic events

Also Published As

Publication number Publication date
WO2002039122A3 (en) 2004-02-26
US20030166017A1 (en) 2003-09-04
WO2002039122A2 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
AU2001249881A1 (en) Method of treating the heart
AU2002338265A1 (en) Molecules for disease detection and treatment
AU2001275177A1 (en) Cardiac disease treatment and device
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
AU2001281369A1 (en) Cardiac disease treatment and device
AU2002241520A1 (en) Blood assessment of injury
AU2002220151A1 (en) Method and system for the detection of heart disease
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2001286983A1 (en) Method of treatment
AU2001260774A1 (en) Bio-support and preparing method of the same
AU2002329784A1 (en) Molecules for disease detection and treatment
AU2001245414A1 (en) Treatment of allergies
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
AU5565401A (en) Materials and methods for the treatment of depression
AU2002364890A1 (en) Molecules for disease detection and treatment
AU2001241709A1 (en) Molecules for disease detection and treatment
AU2001262177A1 (en) Method of treatment
AU2002243539A1 (en) Molecules for disease detection and treatment
AU2002347899A1 (en) Molecules for disease detection and treatment
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
AU2001253560A1 (en) Methods of treatment
AU2002239543A1 (en) Molecules for disease detection and treatment
AU2002359567A1 (en) Molecules for disease detection and treatment